21 CFR 820.75
Lack of or inadequate process validation
- Inspections citing it: 2,407
- Of those classified, ended OAI: 25%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 820.75(a)
- 1,850 · Lack of or inadequate process validation
- 820.75(b)
- 265 · Lack/Inad procedure-Monitoring/Control of Validated Proces
- 820.75(c)
- 203 · Process changes - review, evaluation and revalidation
- 820.75(b)(2)
- 89 · Documentation of validated process performance
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Marson Medical, Inc.United States · Jan 16, 2026
- Ashland Specialty Ingredients, G.P.United States · Dec 22, 2025
- BioMed Laboratories, LLC.United States · Dec 19, 2025
- ZIOSOFT, INC.Japan · Dec 18, 2025
- DiAgam Societe Anonyme (S.A.)Belgium · Dec 18, 2025
- KCI POLYMEDICS BVBelgium · Dec 11, 2025
- Creative Foam Corporation - BremenUnited States · Nov 24, 2025
- OLYMPUS MEDICAL SYSTEMS CORP. Hinode PlantJapan · Nov 21, 2025
- Gyrus ACMI, Inc.United States · Nov 12, 2025
- Drake Precision Dental LaboratoryUnited States · Nov 5, 2025
- IsoTis OrthoBiologics, Inc.United States · Oct 17, 2025
- G3 MedicalUnited States · Sep 26, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR